Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.
Endocrinol Diabetes Nutr (Engl Ed)
; 71(3): 124-132, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38555109
ABSTRACT
OBJECTIVES:
Some concerns persist regarding the safety of semaglutide. The objective of this updated meta-analysis is to assess the risk of acute pancreatitis with the use of semaglutide, assessing the results according to the different administration regimens.METHODS:
We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis. This meta-analysis was performed in line with PRISMA guidelines. A global and stratified analysis according to the therapeutic scheme used was performed using the fixed-effects model.RESULTS:
Twenty-one eligible trials of semaglutide, including 34,721 patients, were identified and considered eligible for the analyses. Globally, semaglutide therapy was not associated with an increased risk of acute pancreatitis (OR 0.7; 95% CI 0.5-1.2, I2 0%). When we analysed the studies according to the different schemes used, the results were similar (group with oral semaglutide OR 0.40; 95% CI 0.10-1.60, I2 0%; group with low subcutaneous doses of semaglutide OR 0.80; 95% CI 0.40-1.90, I2 0%; group with high subcutaneous doses of semaglutide OR 0.70; 95% CI 0.50-1.20, I2 0%; interaction p-value=0.689).CONCLUSION:
This updated meta-analysis demonstrates that the use of semaglutide is not associated with an increased risk of acute pancreatitis compared to placebo. In the stratified analysis, the results were similar with the different semaglutide regimens analysed.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pancreatitis
Límite:
Humans
Idioma:
En
Revista:
Endocrinol Diabetes Nutr (Engl Ed)
Año:
2024
Tipo del documento:
Article
Pais de publicación:
España